Androgens and cardiovascular risk: a series ...
Type de document :
Article dans une revue scientifique: Article original
PMID :
URL permanente :
Titre :
Androgens and cardiovascular risk: a series of case report in the french and canadian pharmacovigilance databases
Auteur(s) :
Rochoy, Michael [Auteur]
Université de Lille
Thomas, R. [Auteur]
Université de Lille
Bene, Johana [Auteur]
Université de Lille
Deleplanque, Denis [Auteur]
Université de Lille
Vantyghem, Marie-Christine [Auteur]
Recherche translationnelle sur le diabète (RTD) - U1190
GAUTIER, Sophie [Auteur]
Troubles cognitifs dégénératifs et vasculaires - U 1171 - EA 1046 [TCDV]
Troubles cognitifs dégénératifs et vasculaires - U1171
Deplanque, Dominique [Auteur]
Troubles cognitifs dégénératifs et vasculaires - U 1171 - EA 1046 [TCDV]
Troubles cognitifs dégénératifs et vasculaires - U1171
Université de Lille
Thomas, R. [Auteur]
Université de Lille
Bene, Johana [Auteur]
Université de Lille
Deleplanque, Denis [Auteur]
Université de Lille
Vantyghem, Marie-Christine [Auteur]
Recherche translationnelle sur le diabète (RTD) - U1190
GAUTIER, Sophie [Auteur]
Troubles cognitifs dégénératifs et vasculaires - U 1171 - EA 1046 [TCDV]
Troubles cognitifs dégénératifs et vasculaires - U1171
Deplanque, Dominique [Auteur]
Troubles cognitifs dégénératifs et vasculaires - U 1171 - EA 1046 [TCDV]
Troubles cognitifs dégénératifs et vasculaires - U1171
Titre de la revue :
Progrès en Urologie
Nom court de la revue :
Prog. Urol.
Numéro :
28
Pagination :
315-321
Date de publication :
2018-05
ISSN :
1166-7087
Mot(s)-clé(s) en anglais :
Androgen deficiency in male aging
Pharmacovigilance
Testosterone replacement therapy
Cardiovascular events
Pharmacovigilance
Testosterone replacement therapy
Cardiovascular events
Discipline(s) HAL :
Sciences du Vivant [q-bio]
Résumé en anglais : [en]
BACKGROUND: Age-related androgenic deficiency (DALA) is a pathology that is increasingly cited in recent publications. The cardiovascular risk of testosterone is debated: present for the FDA, absent for the European Medicines ...
Lire la suite >BACKGROUND: Age-related androgenic deficiency (DALA) is a pathology that is increasingly cited in recent publications. The cardiovascular risk of testosterone is debated: present for the FDA, absent for the European Medicines Agency in 2015. Our objective was to analyze the association between androgens and vascular pathologies in adverse reactions reported in pharmacovigilance databases. METHODS: We conducted a retrospective case series study of the French and Canadian pharmacovigilance databases for the period 2005-2015. Cases were defined as the association of the occurrence of a cardiovascular event (myocardial infarction or stroke) and the presence of testosterone in the treatment of patients. RESULTS: Of the 10 years analyzed, 12 French cases and 6 Canadian cases (representing 13 MIs and 5 strokes) were recorded in men aged 55 years on average. All were doubtful: differential diagnoses were possible (2.4 confounding conditions on average per patient) and overall cardiovascular risk was high for the majority of cases. CONCLUSIONS: Our study shows a very low report of cardiovascular effects under testosterone, all doubtful. Pending further studies, it seems reasonable to consider the cardiovascular risk of patients who are candidates for hormone therapy for age-related androgen deficiency. METHODS: 3.Lire moins >
Lire la suite >BACKGROUND: Age-related androgenic deficiency (DALA) is a pathology that is increasingly cited in recent publications. The cardiovascular risk of testosterone is debated: present for the FDA, absent for the European Medicines Agency in 2015. Our objective was to analyze the association between androgens and vascular pathologies in adverse reactions reported in pharmacovigilance databases. METHODS: We conducted a retrospective case series study of the French and Canadian pharmacovigilance databases for the period 2005-2015. Cases were defined as the association of the occurrence of a cardiovascular event (myocardial infarction or stroke) and the presence of testosterone in the treatment of patients. RESULTS: Of the 10 years analyzed, 12 French cases and 6 Canadian cases (representing 13 MIs and 5 strokes) were recorded in men aged 55 years on average. All were doubtful: differential diagnoses were possible (2.4 confounding conditions on average per patient) and overall cardiovascular risk was high for the majority of cases. CONCLUSIONS: Our study shows a very low report of cardiovascular effects under testosterone, all doubtful. Pending further studies, it seems reasonable to consider the cardiovascular risk of patients who are candidates for hormone therapy for age-related androgen deficiency. METHODS: 3.Lire moins >
Langue :
Anglais
Audience :
Internationale
Vulgarisation :
Non
Établissement(s) :
CHU Lille
CNRS
Inserm
Université de Lille
CNRS
Inserm
Université de Lille
Collections :
Date de dépôt :
2019-12-09T18:18:30Z
2021-06-25T08:39:08Z
2024-06-05T12:11:03Z
2021-06-25T08:39:08Z
2024-06-05T12:11:03Z